# BLIND POINT-IN-TIME FORECASTING TASK
You are a professional regulatory forecaster. This file contains 20 independent forecasting snapshots about
DIFFERENT regulatory matters. Treat each snapshot on its own; do not carry information between snapshots.

Rules:
1. For each snapshot, "today" is its CUTOFF DATE. Use only the evidence shown plus general knowledge of how the
   regulatory process usually behaves (base rates, typical durations). Do not use any world-state fact learned after
   the cutoff: later election results, leadership changes, court rulings, agency decisions, dates or outcomes are
   unknown, even if you remember them. A future event stated in cutoff-valid evidence may be considered only as an
   uncertain plan or possibility, never as a later-known result. Every factual driver in "notes" or "scenarios" must
   be supported by the shown evidence or be a general process base rate.
2. Do NOT use any specific memory of what happened to this particular matter after the cutoff. If you recognise the
   matter and believe you know its later outcome, set "recognised_outcome": true and forecast from cutoff-valid
   evidence only. Never state or hint at the remembered result.
3. The evidence shown may be only a subset of what was public; do not infer anything from the absence of a
   document type. Some snapshots show no documents at all — then forecast from title, regulator, process and date.
4. "Decisive action" is defined per snapshot. Probabilities in "p" are CUMULATIVE: probability the decisive action
   is published within 7/30/60/90/180 days AFTER the cutoff (non-decreasing; "180d" is the headline action
   probability). Delays, stalls, withdrawals and no-action outcomes are common in regulation: be calibrated, use
   the full 0–1 range when evidence warrants, and do not default to 0.5.
5. "next": the NEXT official step within 180 days (mutually exclusive, sums to 1): final_action,
   revised_or_further_consultation (revised draft, supplemental proposal, extended/reopened comment period,
   further consultation or hearing), formal_withdrawal, no_further_official_step.
6. "content": CONDITIONAL on the decisive action happening, its form relative to the most recent proposal visible
   (sums to 1): as_proposed (substantially as proposed), softened (narrower scope, lower stringency, higher
   thresholds, longer transition, carve-outs), tightened, mixed (some softened, some tightened),
   different_mechanism.
7. "scenarios": up to 3 concrete policy-content scenarios CONDITIONAL on action (probabilities sum ≤ 1), each with
   a short mechanism and, where the evidence has numbers (thresholds, rates, dates, amounts), predicted
   parameter ranges. Cite evidence labels (E1, E2 …) that support/contradict it.
8. If the evidence is too thin to forecast meaningfully, set "insufficient_evidence": true but still give your best
   base-rate probabilities.

OUTPUT: read the output file named in your instructions (it contains a placeholder) and replace its ENTIRE content
with ONE JSON object of exactly this shape (no comments, no trailing text):
{"forecasts": [
  {"id": "<snapshot id>",
   "p": {"7d": 0.00, "30d": 0.00, "60d": 0.00, "90d": 0.00, "180d": 0.00},
   "next": {"final_action": 0.00, "revised_or_further_consultation": 0.00, "formal_withdrawal": 0.00, "no_further_official_step": 0.00},
   "content": {"as_proposed": 0.00, "softened": 0.00, "tightened": 0.00, "mixed": 0.00, "different_mechanism": 0.00},
   "scenarios": [{"s": "short label", "p": 0.00, "mech": "mechanism, <=25 words", "params": {"parameter": "predicted range"}, "ev": ["E1"], "contra": []}],
   "notes": "<=40 words: main drivers of your forecast",
   "missing": ["<=3 items of missing information that would most change the forecast"],
   "recognised_outcome": false,
   "insufficient_evidence": false}
]}
One entry per snapshot, in any order, using the exact snapshot ids below.

---
## SNAPSHOT Sd3701be948
CUTOFF DATE (today): 2024-03-01
Regulator: FDA (US)
Matter: FDA draft guidance: Voluntary Malfunction Summary Reporting Program for Manufacturers
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S6822b74057
CUTOFF DATE (today): 2023-01-27
Regulator: FDA (US)
Matter: FDA draft guidance: Mitigation Strategies To Protect Food Against Intentional Adulteration
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S5102e60219
CUTOFF DATE (today): 2026-06-08
Regulator: SEBI (IN)
Matter: SEBI consultation: reviewing base price and price band methodology for Exchange Traded Funds
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.
---
## SNAPSHOT S52c27d6bbf
CUTOFF DATE (today): 2026-02-21
Regulator: SEBI (IN)
Matter: SEBI consultation: permitting net settlement of funds for Foreign Portfolio Investor cash-market transactions
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2026-01-16 | official-forward (B) | consultation_paper | "Consultation Paper on proposal to permit netting of funds for transactions done by Foreign Portfolio Investors (FPIs)" | www.sebi.gov.in
   Claims: Proposes to permit net settlement of funds for outright transactions (purchase or sale, not both) done by FPIs in the cash market. / Notes FPIs currently settle transactions with custodians on a gross basis (Regulation 20(4), FPI Regulations 2019), adding funding costs and forex slippage; custodians already net-settle with clearing corporations. / States securities settlement would continue on a gross basis and STT/stamp duty would continue to be levied on a delivery basis; only the funds leg would be netted.
   Excerpt: In terms of Regulation 20(4) of SEBI (FPI) Regulations, 2019, FPIs are required to transact in securities in India only on the basis of taking and giving delivery of securities purchased or sold... SEBI has received feedback regarding review of the current practice in order to enhance operational efficiency and reduce cost of funding for FPIs. It is proposed to permit netting of funds for transactions done by FPIs in cash market.
---
## SNAPSHOT Sa61dda0e68
CUTOFF DATE (today): 2023-04-25
Regulator: FDA (US)
Matter: FDA draft guidance: Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S13fbc45234
CUTOFF DATE (today): 2026-06-12
Regulator: SEBI (IN)
Matter: SEBI consultation: 'Green-Channel' document-acknowledgement mechanism for launch of Alternative Investment Fund schemes
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.
---
## SNAPSHOT S5e66c94da8
CUTOFF DATE (today): 2021-04-08
Regulator: FDA (US)
Matter: FDA draft guidance: Biomarkers and Surrogate Endpoints in Clinical Studies To Support Effectiveness of New Animal Drugs
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S654a39b01c
CUTOFF DATE (today): 2021-07-29
Regulator: FDA (US)
Matter: FDA draft guidance: Patient Engagement in the Design and Conduct of Medical Device Clinical Investigations
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S22671e5903
CUTOFF DATE (today): 2026-06-12
Regulator: SEBI (IN)
Matter: SEBI consultation: amendments to the Issue and Listing of Securitised Debt Instruments and Security Receipts Regulations
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.
---
## SNAPSHOT S43dbe996b4
CUTOFF DATE (today): 2024-01-23
Regulator: FDA (US)
Matter: FDA draft guidance: Measuring Growth and Evaluating Pubertal Development in Pediatric Clinical Trials
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT Sea0ea85cef
CUTOFF DATE (today): 2022-10-15
Regulator: FDA (US)
Matter: FDA draft guidance: Peripheral Percutaneous Transluminal Angioplasty and Specialty Catheters-Premarket Notification (510(k)) Submissions
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT Sa64549a749
CUTOFF DATE (today): 2025-08-19
Regulator: FDA (US)
Matter: FDA draft guidance: Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2022-06-30 | official-forward (B) | draft_guidance_availability_notice | "Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments; Draft Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Patient- Focused Drug Development: Selecting, Developing, or Modifying Fit-for- Purpose Clinical Outcome Assessments." This guidance (Guidance 3) is the third in a series of fou
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Patient- Focused Drug Development: Selecting, Developing, or Modifying Fit-for- Purpose Clinical Outcome Assessments." This guidance (Guidance 3) is the third in a series of four methodological patient-focused drug development (PFDD) guidance documents that describe how stakeholders (patients, researchers, medical product developers, and others) can collect and submit patient experience data and other relevant information from patients and caregivers to be used for medical product development and regulatory decision-making. When finalized, Guidance 3 will represent the current thinking of the Center for Drug Evaluation and Research, the Center for Biologics Evaluation and Research, and the Center for Devices and Radiological Health on this topic.
---
## SNAPSHOT S08373fdea5
CUTOFF DATE (today): 2024-07-19
Regulator: FDA (US)
Matter: FDA draft guidance: Review of Drug Master Files in Advance of Certain Abbreviated New Drug Application Submissions Under Generic Drug User Fee Amendments
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2022-10-06 | official-forward (B) | draft_guidance_availability_notice | "Review of Drug Master Files in Advance of Certain Abbreviated New Drug Application Submissions Under Generic Drug User Fee Amendments; Draft Guidance for Industry; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Review of Drug Master Files in Advance of Certain ANDA Submissions Under GDUFA." The purpose of this draft guidance is to provide information and recommendations on the Generic 
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Review of Drug Master Files in Advance of Certain ANDA Submissions Under GDUFA." The purpose of this draft guidance is to provide information and recommendations on the Generic Drug User Fee Amendments (GDUFA) III program enhancements agreed upon by the Agency and industry in "GDUFA Reauthorization Performance Goals and Program Enhancements Fiscal Years 2023-2027" (GDUFA III commitment letter), related to the early assessment of certain Type II drug master files (DMFs) 6 months prior to the submission of certain abbreviated new drug applications (ANDAs) or prior approval supplements (PASs). This draft guidance describes the process outlined in the GDUFA III commitment letter in greater detail and provides recommendations to DMF holders on how to provide the relevant information to FDA.
---
## SNAPSHOT S0e4a5e7ea8
CUTOFF DATE (today): 2026-07-07
Regulator: SEBI (IN)
Matter: SEBI consultation: reviewing the pre-open call auction price-discovery mechanism for IPO listings and re-listed scrips
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.
---
## SNAPSHOT Sc1688a63b6
CUTOFF DATE (today): 2021-01-13
Regulator: FDA (US)
Matter: FDA draft guidance: Technical Considerations for Demonstrating Reliability of Emergency-Use Injectors Submitted Under a Biologics License Application, New Drug Application, or Abbreviated New Drug ...
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S5201344288
CUTOFF DATE (today): 2024-01-15
Regulator: FDA (US)
Matter: FDA draft guidance: Charging for Investigational Drugs Under an Investigational New Drug Application: Questions and Answers
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT Sc827e25536
CUTOFF DATE (today): 2023-09-07
Regulator: FDA (US)
Matter: FDA draft guidance: Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2022-03-10 | official-forward (B) | draft_guidance_availability_notice | "Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs; Draft Guidance for Industry; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a revised draft guidance entitled "Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs." This revised draft guidance addresses the verification systems that manufacturers, repa
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a revised draft guidance entitled "Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs." This revised draft guidance addresses the verification systems that manufacturers, repackagers, wholesale distributors, and dispensers must have in place to comply with the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Drug Supply Chain Security Act (DSCSA). Specifically, this revised draft guidance covers the statutory verification system requirements that include the quarantine and investigation of a product determined to be suspect and the quarantine and disposition of a product determined to be illegitimate. The revised draft guidance also addresses the statutory requirement for notification to the Agency of a product that has been cleared by a manufacturer, repackager, wholesale distributor, or dispenser (also referred to as "trading partners") after a suspect product investigation because it is determined that the product is not an illegitimate product. Finally, the revised draft guidance addresses the statutory requirement for responding to requ
---
## SNAPSHOT S01e30fe39c
CUTOFF DATE (today): 2026-07-13
Regulator: SEBI (IN)
Matter: SEBI consultation: reviewing use of historical price scenarios in stress testing for the Commodity Derivatives Segment
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2026-02-05 | official-forward (B) | draft_circular_for_comment | "Consultation Paper On Draft Circular on Review of Inclusion of Historical Scenarios in Stress Testing and Coverage of Settlement Guarantee Fund for Commodity Derivatives Segment" | www.sebi.gov.in
   Claims: Proposes to review the Z-score threshold (currently 10) used to cap extreme historical price movements in peak-historical-return stress-testing scenarios for the Commodity Derivatives Segment's Core Settlement Guarantee Fund. / Also proposes to review the coverage requirement of the Settlement Guarantee Fund for the Commodity Derivatives Segment. / Describes the existing framework's 15-year historical lookback period for computing maximum percentage rise/fall (Scenarios 1A/1B).
   Excerpt: SEBI Master Circular... for Commodity Derivatives Segment dated Aug 04, 2023, inter alia, prescribes norms related to Core Settlement Guarantee Fund (SGF). The extant provisions pertaining to applicable value of Z-Score (for the purpose of stress testing) and coverage of SGF, as provided in paragraph 22 of Annexure O of the said circular are as follows: ...Price movements corresponding to a Z-score of 10 will replace extreme price movements beyond that threshold in peak historical returns of all the commodities. SEBI has received representations to review the aforementioned extant provision related to Z-Score for Commodity Derivatives Market.
---
## SNAPSHOT Sfbf2d0f1e9
CUTOFF DATE (today): 2025-07-08
Regulator: FDA (US)
Matter: FDA draft guidance: Benefit-Risk Considerations for Product Quality Assessments
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2022-05-09 | official-forward (B) | draft_guidance_availability_notice | "Benefit-Risk Considerations for Product Quality Assessments; Draft Guidance for Industry; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Benefit- Risk Considerations for Product Quality Assessments." This guidance describes the benefit-risk principles applied by FDA when conducting product quality-related assessm
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Benefit- Risk Considerations for Product Quality Assessments." This guidance describes the benefit-risk principles applied by FDA when conducting product quality-related assessments of chemistry, manufacturing, and controls (CMC) information submitted for FDA assessment as part of original new drug applications (NDAs), original biologics license applications (BLAs), or supplements to such applications, in addition to other information (e.g., inspectional findings) available to FDA during its assessment. This guidance discusses how FDA assesses risks, sources of uncertainty, and possible mitigation strategies for a product quality-related issue and how those considerations inform FDA's understanding of the potential effect on a product. This guidance also discusses how unresolved product quality issues may be addressed in the context of regulatory decision making. The guidance notes that product quality assessments are also done for abbreviated new drug applications (ANDAs), and it discusses how, in certain rare circumstances, unresolved product quality issues m
---
## SNAPSHOT Sa70d3b82ed
CUTOFF DATE (today): 2022-09-16
Regulator: FDA (US)
Matter: FDA draft guidance: The Use of Published Literature in Support of New Animal Drug Applications
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.